Inclusion Criteria : 
  -  Patients who fulfilled the following criteria were included in the study : 
  -  Adult renal transplant patients (  ≥ 21 years )  , 
  -  Informed consent , 
  -  Stable maintenance subcutaneous ESA therapy with constant dose interval during the last 2 months , 
  -  Haemoglobin ( Hb ) ≥ 10 mg / dL ( Hct 32 % )  , 
  -  Transferrin saturation ( TSAT ) ≥ 20 % ( during the screening phase )  , 
  -  and serum ferritin ≥ 100 ng / mL
Exclusion Criteria : 
We excluded patients with the following criteria : 
  -  Acute or chronic bleeding , or erythrocyte transfusion , within the preceding 8 weeks.  change in Hb level ≥ 2 g / dL during screening phase , 
  -  Hemolytic anemia , 
  -  Recent infection or rejection , 
  -  Diastolic blood pressure > 100 mmHg or discontinuation of ESA due to hypertension in the 6 months prior to study , 
  -  Vitamin B12 or folic acid deficiency , 
  -  Uncontrolled or secondary hyperparathyroidism , 
  -  Acute or chronic systemic inflammatory disease and / or C - reactive protein ( CRP ) > 30 mg / L , 
  -  Hemodialysis due to failure of a kidney transplant , 
  -  and malignancy
